Develops precision therapies for genetically defined cancers. Focuses on cancers with alterations in mTOR pathway genes. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 59% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 13.3× for every dollar of annual revenue.
Analysts' average target sits 20% below today's price.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 95% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 59% a year on average.
Sales run at $7.1M a year. A small number, but proof the product has real buyers.
There is $145.7M in the vault; even if every debt were paid off, $145.7M would remain.
A loss of $20.6M against $7.1M in annual sales. And on top of that, sales fell from the year before.
The stock trades 20% above the average analyst price target.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.